Please assess the completion status of the following clinical trial:

Trial Title: Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Progressed from VEG105192 study treatment~* Patient's VEG105192 was placebo~* Baseline has good organ function~Exclusion criteria:~* No brain metastasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pazopanib arm (Type: EXPERIMENTAL): This was a single arm study, therefore no control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).